Clinical Trial Update: Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (LILAC-TIMI 76) is evaluating the efficacy and safety of abeLacimab in high‑risk atrial fibrillation patients who cannot take oral anti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• abeLacimab (abeLacimab)

Snippet

Sponsor: Anthos Therapeutics, Inc. | Conditions: Atrial Fibrillation (AF) | Phase 3 | Status: RECRUITING